A disruptive medical device to enable proton therapy as non-invasive and automated treatment of heart arrhythmias

2026-07-22

Heart arrhythmia is a major worldwide public health problem, accounting for 15–20% of all deaths. Heart arrhythmias affects over 15 million people in Europe and North America and this number is expected to double in the next 50 years due to the aging population and lifestyle changes. Catheter ablation is the current gold standard for heart arrhythmia treatment. The surgical procedure is performed by introducing a catheter under anaesthesia into the heart chambers, to ablate selected target regions by applying heat. This invasive procedure requires patient hospitalization, a staff of 10 doctors, and has a high risk of complications, such as bleeding, infection and damage to heart valves and blood vessels. EBAMed developed Cardio-kit, a non-invasive medical device for heart arrhythmia treatment using proton therapy. It is a plug&play system that can be integrated into existing proton machines. Cardio-kit enables monitoring of heart movements in real time, and automatically adjusts the Stop/Go activity of the proton therapy machine based on the phase of the cardiac cycle in which to intervene. Cardio-kit ensures an accurate, effective and safe treatment of the moving target within the heart at the right time. In this way, Cardio-kit facilitates an out-patient procedure, as it does not require any hospitalization or sedation. The procedure is quick, safe, painless and suitable for any age and health condition patient with no side-effects. During the phase 1 project, a go-to-market strategy and a supply chain will be established, as well as further development plan will be drafted. Within the overall innovation project, EBAMed will finalize its engineering of Cardio-kit before scaling up, and perform clinical validation with partner hospitals.

Switzerland

2026-02-15